Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study

Nashan "Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group" Lancet (1997) 10.1016/s0140-6736(97)09278-7

[2]

Merion "Cyclosporine: five years' experience in cadaveric renal transplantation" N Engl J Med (1984) 10.1056/nejm198401193100303

[3]

"Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group" Lancet (1995) 10.1016/s0140-6736(95)92534-1

[4]

"A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group" Transplantation (1996) 10.1097/00007890-199604150-00008

[5]

Kahan "Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group" Lancet (2000) 10.1016/s0140-6736(00)02480-6

[6]

Lentine "The implications of acute rejection for allograft survival in contemporary U.S. kidney transplantation" Transplantation (2012) 10.1097/tp.0b013e318259407f

[7]

Nankivell "Rejection of the kidney allograft" N Engl J Med (2010) 10.1056/nejmra0902927

[8]

Lodhi "Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success" Am J Transplant (2011) 10.1111/j.1600-6143.2011.03539.x

[9]

Immunosuppression and the Risk of Post-Transplant Malignancy Among Cadaveric First Kidney Transplant Recipients

Rami T Bustami, Akinlolu O Ojo, Robert A Wolfe et al.

American Journal of Transplantation 2004 10.1046/j.1600-6135.2003.00274.x

[10]

Dharnidharka "An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States" Transplantation (2009) 10.1097/tp.0b013e31819cc383

[11]

Luan "Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period" Am J Transplant (2008) 10.1111/j.1600-6143.2008.02328.x

[12]

Dharnidharka "Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study" Pediatr Transplant (2002) 10.1034/j.1399-3046.2002.00021.x

[13]

USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States Bethesda, MD National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2013

[14]

Kutinova "The incidence and costs of sepsis and pneumonia before and after renal transplantation in the United States" Am J Transplant (2006) 10.1111/j.1600-6143.2005.01156.x

[15]

Engels "Spectrum of cancer risk among US solid organ transplant recipients" JAMA (2011) 10.1001/jama.2011.1592

[16]

Kasiske "Cancer after kidney transplantation in the United States" Am J Transplant (2004) 10.1111/j.1600-6143.2004.00450.x

[17]

Lentine "Incidence and predictors of myocardial infarction after kidney transplantation" J Am Soc Nephrol (2005) 10.1681/asn.2004070580

[18]

Lentine "De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications" Am J Kidney Dis (2005) 10.1053/j.ajkd.2005.06.019

[19]

Boudreaux "The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients" Transplantation (1987) 10.1097/00007890-198709000-00010

[20]

Vincenti "A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients" Am J Transplant (2008) 10.1111/j.1600-6143.2007.02057.x

[21]

Luan "New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression" Transplantation (2011) 10.1097/tp.0b013e318203c25f

[22]

Buchler "Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids" Am J Transplant (2007) 10.1111/j.1600-6143.2007.01976.x

[23]

Guba "Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial" Transplantation (2010) 10.1097/tp.0b013e3181e11798

[24]

Ekberg "Reduced exposure to calcineurin inhibitors in renal transplantation" N Engl J Med (2007) 10.1056/nejmoa067411

[25]

Vincenti "A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)" Am J Transplant (2011) 10.1111/j.1600-6143.2009.03005.x

[26]

Groth "Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group" Transplantation (1999) 10.1097/00007890-199904150-00017

[27]

Ekberg "Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study" Am J Transplant (2007) 10.1111/j.1600-6143.2006.01645.x

[28]

Flechner "The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients" Am J Transplant (2011) 10.1111/j.1600-6143.2011.03573.x

[29]

Holdaas "Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study" Transplantation (2011) 10.1097/tp.0b013e318224c12d

[30]

Lebranchu "Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study" Am J Transplant (2009) 10.1111/j.1600-6143.2009.02615.x

[31]

Mathew "Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies" Clin Transplant (2004) 10.1111/j.1399-0012.2004.00188.x

[32]

Axelrod "National variation in use of immunosuppression for kidney transplantation: a call for evidence-based regimen selection" Am J Transplant (2016) 10.1111/ajt.13758

[33]

Kasiske "Diabetes mellitus after kidney transplantation in the United States" Am J Transplant (2003) 10.1034/j.1600-6143.2003.00010.x

[34]

Lentine "Early clinical complications after ABO-incompatible live-donor kidney transplantation: a national study of Medicare-insured recipients" Transplantation (2014) 10.1097/tp.0000000000000029

[35]

Grulich "Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis" Lancet (2007) 10.1016/s0140-6736(07)61050-2

[36]

Gheorghian "The implications of acute rejection and reduced allograft function on health care expenditures in contemporary US kidney transplantation" Transplantation (2012) 10.1097/tp.0b013e318255f839

[37]

Webster "Interleukin 2 receptor antagonists for kidney transplant recipients" Cochrane Database Syst Rev (2010)

[38]

Hall "Association of antibody induction immunosuppression with cancer after kidney transplantation" Transplantation (2015) 10.1097/tp.0000000000000449

[39]

Palepu "New-onset diabetes mellitus after kidney transplantation: current status and future directions" World J Diabetes (2015) 10.4239/wjd.v6.i3.445

[40]

Alangaden "Infectious complications after kidney transplantation: current epidemiology and associated risk factors" Clin Transplant (2006) 10.1111/j.1399-0012.2006.00519.x

[41]

Kauffman "Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies" Transplantation (2005) 10.1097/01.tp.0000184006.43152.8d

[42]

Yanik "Sirolimus use and cancer incidence among US kidney transplant recipients" Am J Transplant (2015) 10.1111/ajt.12969

[43]

Karia "Association of sirolimus use with risk for skin cancer in a mixed-organ cohort of solid-organ transplant recipients with a history of cancer" JAMA Dermatol (2016) 10.1001/jamadermatol.2015.5548

[44]

Lentine "Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure" Clin J Am Soc Nephrol (2008) 10.2215/cjn.03080707

Cited By

55

Responsible Use of Artificial Intelligence to Improve Kidney Care

Navdeep Tangri, Wisit Cheungpasitporn · 2025

Journal of the American Society of...

Metrics

55

Citations

44

References

Details

Published: Sep 28, 2016
Vol/Issue: 29(11)
Pages: 1226-1236
License: View

Authors

V

Vikas R. Dharnidharka

Washington University in St. Louis School of Medicine; Saint Louis MO USA

M

Mark A. Schnitzler

Saint Louis University School of Medicine; Saint Louis MO USA

J

Jiajing Chen

Saint Louis University School of Medicine; Saint Louis MO USA

D

Daniel C. Brennan

Washington University in St. Louis School of Medicine; Saint Louis MO USA

D

David Axelrod

Eastern Carolina University; Greeneville NC USA

D

Dorry L. Segev

Johns Hopkins University; Baltimore MD USA

K

KENNETH B. SCHECHTMAN

Washington University in St. Louis School of Medicine; Saint Louis MO USA

J

Jie Zheng

Washington University in St. Louis School of Medicine; Saint Louis MO USA

K

Krista L. Lentine

Saint Louis University School of Medicine; Saint Louis MO USA

Funding

National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases Award: R01DK102981

Cite This Article

Vikas R. Dharnidharka, Mark A. Schnitzler, Jiajing Chen, et al. (2016). Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. Transplant International, 29(11), 1226-1236. https://doi.org/10.1111/tri.12850

Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study

You May Also Like